{"id":14489,"date":"2020-06-05T18:50:52","date_gmt":"2020-06-05T16:50:52","guid":{"rendered":"https:\/\/dzl.de\/supported-investigator-initiated-trials\/"},"modified":"2024-04-23T17:06:31","modified_gmt":"2024-04-23T15:06:31","slug":"supported-investigator-initiated-trials","status":"publish","type":"page","link":"https:\/\/dzl.de\/en\/organization\/supported-investigator-initiated-trials\/","title":{"rendered":"Supported Investigator Initiated Trials"},"content":{"rendered":"<table style=\"width: 99.7947%; height: 1041px;\">\n<thead>\n<tr style=\"height: 51px;\">\n<td style=\"height: 10px; width: 18.1914%;\">\n<h6><span style=\"text-decoration: underline;\">Coordinator(s)\/ scientist(s)<\/span><\/h6>\n<\/td>\n<td style=\"height: 10px; width: 15.7729%;\">\n<h6><span style=\"text-decoration: underline;\">Disease Area<\/span><\/h6>\n<\/td>\n<td style=\"height: 10px; width: 12.2801%;\">\n<h6><span style=\"text-decoration: underline;\">DZL Partner Site(s) involved<\/span><\/h6>\n<\/td>\n<td style=\"height: 10px; width: 52.9144%;\">\n<h6><span style=\"text-decoration: underline;\">Title<\/span><\/h6>\n<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"height: 68px;\">\n<td style=\"height: 84px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">S. Herold \/ T. Welte\u2020<\/span><\/td>\n<td style=\"height: 84px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Acute Lung Injury<\/span><\/td>\n<td style=\"height: 84px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">UGMLC, BREATH<\/span><\/td>\n<td style=\"height: 84px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>GI HOPE<\/strong>: Promotion of host defense and alveolar barrier regeneration by inhaled GM-CSF in patients with pneumonia-associated ARDS<\/span><\/td>\n<\/tr>\n<tr style=\"height: 51px;\">\n<td style=\"height: 125px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">M. Kreuter \/ C. Vogelmeier \/ F. Herth<\/span><\/td>\n<td style=\"height: 125px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">COPD<\/span><\/td>\n<td style=\"height: 125px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">UGMLC, TLRC<\/span><\/td>\n<td style=\"height: 125px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>ExperTENTION<\/strong>: Exploring efficacy of peridontal treatment on systemic inflammation and for prevention of exacerbations in patients with COPD: A multi-center, prospective, randomized, controlled, parallel-group pilot study<\/span><\/td>\n<\/tr>\n<tr style=\"height: 51px;\">\n<td style=\"height: 83px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">M. Reck \/ O. Ammerpohl<\/span><\/td>\n<td style=\"height: 83px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Lung Cancer<\/span><\/td>\n<td style=\"height: 83px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">UGMLC<\/span><\/td>\n<td style=\"height: 83px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>EMO-Lung<\/strong>: Monitoring of patients with NLCLC \u2013 epigenetic analysis of liquid biopsies and RNA-analysis in exhaled breath condensates<\/span><\/td>\n<\/tr>\n<tr style=\"height: 68px;\">\n<td style=\"height: 69px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">H. Schulz \/ S. Meiners \/ J. Behr \/ C. Vogelmeier<\/span><\/td>\n<td style=\"height: 69px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">COPD<\/span><\/td>\n<td style=\"height: 69px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">CPC-M, UGMLC<\/span><\/td>\n<td style=\"height: 69px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>PBMC<\/strong>: Proteasom Function as a Bio-Marker for COPD<\/span><\/td>\n<\/tr>\n<tr style=\"height: 34px;\">\n<td style=\"height: 91px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">W. Seeger \/ A. Ghofrani<\/span><\/td>\n<td style=\"height: 91px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Pulmonary Hypertension<\/span><\/td>\n<td style=\"height: 91px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">UGMLC<\/span><\/td>\n<td style=\"height: 91px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>Right Heart 3<\/strong>: Influence of specific PAH medication on right ventricular function in patients with pulmonary arterial hypertension<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"height: 17px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">J. Vogel-Claussen<\/span><\/td>\n<td style=\"height: 17px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Pulmonary Hypertension \/ Platform Imaging<\/span><\/td>\n<td style=\"height: 17px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">BREATH<\/span><\/td>\n<td style=\"height: 17px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>Change MRI<\/strong>: Phase III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH.<\/span><\/td>\n<\/tr>\n<tr style=\"height: 102px;\">\n<td style=\"height: 81px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">P. Zabel \/ F. Herth<\/span><\/td>\n<td style=\"height: 81px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">COPD<\/span><\/td>\n<td style=\"height: 81px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">ARCN, TLRC<\/span><\/td>\n<td style=\"height: 81px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>PLBV<\/strong>: Evaluation of non-invasive pursed-lip breathing ventilation in advanced COPD<\/span><\/td>\n<\/tr>\n<tr style=\"height: 68px;\">\n<td style=\"height: 90px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">O. Sommerburg<\/span><\/td>\n<td style=\"height: 90px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Cystic Fibrosis<\/span><\/td>\n<td style=\"height: 90px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">TLRC<\/span><\/td>\n<td style=\"height: 90px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>ANAKIN<\/strong>: Study to evaluate the safety and efficacy of subcutaneous <\/span><span style=\"font-size: 10pt;\">Administration of Anakinra in patients with cystic fibrosis<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"height: 71px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">M. Eichhorn \/ R. Savai<\/span><\/td>\n<td style=\"height: 71px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Lung Cancer<\/span><\/td>\n<td style=\"height: 71px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">TLRC, UGMLC<\/span><\/td>\n<td style=\"height: 71px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>Neomun Trial<\/strong>: Neoadjuvant anti PD-1 immunotherapy in resectable NSCLC.<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"height: 89px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">J. Behr \/ P. Mertsch \/ F. Ringshausen \/ J. Rademacher<\/span><\/td>\n<td style=\"height: 89px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Bronchiectasis Disease<\/span><\/td>\n<td style=\"height: 89px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">CPC-M, BREATH<\/span><\/td>\n<td style=\"height: 89px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>Eradicate<\/strong>: Inhaled Levofloxacin in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection<\/span><\/td>\n<\/tr>\n<tr style=\"height: 18px;\">\n<td style=\"height: 95px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">N. Kneidinger\/ A.\u00d6. Yildirim \/ M. Hecker<\/span><\/td>\n<td style=\"height: 95px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">End-Stage Lung Disease<\/span><\/td>\n<td style=\"height: 95px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">CPC-M, UGMLC<\/span><\/td>\n<td style=\"height: 95px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>CatBOS<\/strong>: Cathepsin-B (CatB) as a new biomarker and therapeutic target for early bronchiolotis obliterans syndrome (BOS) after lung transplantation<\/span><\/td>\n<\/tr>\n<tr style=\"height: 18px;\">\n<td style=\"height: 86px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">J. Vogel-Claussen \/ S. Bohnet \/ M. Reck<\/span><\/td>\n<td style=\"height: 86px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Lung Cancer<\/span><\/td>\n<td style=\"height: 86px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">BREATH, ARCN<\/span><\/td>\n<td style=\"height: 86px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>HANSE Study<\/strong>: Holistic implementation study Assessing a Northern German interdisciplinary lung cancer screening effort<\/span><\/td>\n<\/tr>\n<tr style=\"height: 18px;\">\n<td style=\"height: 33px; width: 18.1914%;\"><span style=\"font-size: 10pt;\">S. Herold \/ T. Welte\u2020<\/span><\/td>\n<td style=\"height: 33px; width: 15.7729%;\"><span style=\"font-size: 10pt;\">Acute Lung Injury<\/span><\/td>\n<td style=\"height: 33px; width: 12.2801%;\"><span style=\"font-size: 10pt;\">UGMLC, BREATH<\/span><\/td>\n<td style=\"height: 33px; width: 52.9144%;\"><span style=\"font-size: 10pt;\"><strong>Cyclosporine A<\/strong>: Early intervention treatment of SARS-CoV-2 with liposomal Cyclosporine A for Inhalation (L-CsA-i) in non-hospitalized patients due to Covid 19<\/span><\/p>\n<div><\/div>\n<\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"height: 17px; width: 18.1914%;\"><\/td>\n<td style=\"height: 17px; width: 15.7729%;\"><\/td>\n<td style=\"height: 17px; width: 12.2801%;\"><\/td>\n<td style=\"height: 17px; width: 52.9144%;\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Coordinator(s)\/ scientist(s) Disease Area DZL Partner Site(s) involved Title S. Herold \/ T. Welte\u2020 Acute Lung Injury UGMLC, BREATH GI HOPE: Promotion of host defense and alveolar barrier regeneration by inhaled GM-CSF in patients with pneumonia-associated ARDS M. Kreuter \/ C. Vogelmeier \/ F. Herth COPD UGMLC, TLRC ExperTENTION: Exploring efficacy of peridontal treatment on [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":620,"parent":14581,"menu_order":80,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"class_list":["post-14489","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/pages\/14489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/comments?post=14489"}],"version-history":[{"count":5,"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/pages\/14489\/revisions"}],"predecessor-version":[{"id":46518,"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/pages\/14489\/revisions\/46518"}],"up":[{"embeddable":true,"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/pages\/14581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/media\/620"}],"wp:attachment":[{"href":"https:\/\/dzl.de\/en\/wp-json\/wp\/v2\/media?parent=14489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}